AcneFeatured PodcastPodcast Highlights

Oral Antibiotics for Acne: Basic Concepts & Practical Considerations

By March 2, 2021April 1st, 2022No Comments

JDD Multimedia

JDD Podcast

Listen Now

How to Listen

Oral Antibiotics for Acne: Basic Concepts & Practical Considerations

Drs. Mahmoud Ghannoum, Emmy Graber & Adam Friedman

 

Antibiotic use for inflammatory skin diseases is a staple in dermatology. Like milk is the answer to a chunky peanut butter sandwich (just go with me on this), so too have tetracycline antibiotics been married to the management of Acne Vulgaris. And just as that delicious combo comes at a fattening cost, the overuse and abuse of antibiotics has an impressive and significant impact both on the risk for antimicrobial resistance and gut/cutaneous dysbiosis.

To get to the piloseabeous unit of the matter, JDD Podcast host Dr. Adam Friedman picks the brains of AAA experts Dr. Emmy Graber and Dr. Mahmoud Ghannoum to provide a true bench to bedside review of the issues at hand. Pop in to learn how to interpret minimum inhibitory concentrations (MIC), understand newly identified information on dysbiosis (including impaired microbiota), and appreciate the implications of indiscriminate use of broad-spectrum antibiotics in acne therapy including the clinical consequence of antibiotic resistance and benefits of narrow-spectrum agents.

Listen Now
Learning Objectives
Upon completion of this podcast participants should be able to:
  • Describe the differences between antibiotic types and their use in acne therapy
  • Discuss interpretation and measurement of MIC, resistance and dysbiosis
  • Summarize the clinical implications of antibiotic resistance
  • Summarize the clinical implications of dysbiosis
This enduring activity is supported by an independent medical education grant provided by Almirall, LLC.
Disclosures
Adam Friedman, MD, FAAD – Grant/Research: Aclaris, CPN, Almirall. Consultant: SanovaWorks, Oakstone Institute, L’oreal, La Roche Posay, Galderma, Aveeno, Valeant, Microcures, Biogen, Pfizer, G&W Laboratories, Novartis, Occulus, Intraderm, Encore, Exeltis, Menlo, Lilly, Aclaris, Dermira, Berg, Allergan, Zylo Therapeutics, Hoth. Speakers’ Bureau: Regeneron, Dermira, Janssen, AbbVie. Major Stock Shareholder: Zylo, Minorcures.
Mahmoud Ghannoum, PhD – Grant/Research: Almirall. Consultant: Almirall.
Emmy M. Graber, MD, MBA – Grant/Research: Ortho Dermatologics. Consultant: Almirall, Digital Diagnostics, Sebacia, SolGel. Speakers’ Bureau: Almirall

You May Also Like

Formulation Foundations: A Peak Behind the Development Curtain

| Dermatology Podcast Archives, Featured Podcast, JDD Highlights, Podcast Highlights | No Comments
iTunes TuneIn Spotify Dr. David Osborne Finding the right formulation is not always a fun endeavor for the practitioner or patient, and can be the make or break for patient…

Reface the Chase: Paradigm shifts in the AD Management Strategy Mentality

| Dermatology Podcast Archives, Featured Podcast, JDD Highlights, Podcast Highlights | No Comments
iTunes TuneIn Spotify Dr. Raj Chovatiya Who doesn't love a good game of "Whack a Mole?" Anyone? Just as you try to stay ahead of those furry, taunting, smiling devils…

Diving into Dyspigmentation: Discoloration Details and Future Directions

| Dermatology Podcast Archives, Featured Podcast, JDD Highlights, Podcast Highlights | No Comments
iTunes TuneIn Spotify Dr. Andrew Alexis Dyspigmentation is defeating....for the patient and the practitioner as it is often a secondary feature of chronic inflammatory skin diseases and often a greater…

Leave a Reply